Clinical Research Directory

Inclusion Criteria:• * Age ≥16 years with newly diagnosed, histologically confirmed AML.Scheduled to receive either:- Cohort A (Intensive): Anthracycline-based induction - Cohort B (Non-Intensive): Venetoclax and / or Hypomethylating Agent based regimens * Baseline LVEF ≥ 50% as measured by standard baseline echocardiography. * Patient provided written, informed consent. Exclusion Criteria: * Prior history of anthracycline or venetoclax\_HMAs exposure. * Pre-existing severe structural heart disease (e.g., severe valvular heart disease, ischemic cardiomyopathy, basal LVEF \<50%). * Persistent hemodynamically unstable arrhythmias. * Poor acoustic windows making reliable 2D-STE tracking impossible.